OncoMatch/Clinical Trials/NCT07284277
TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC)
Is NCT07284277 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies TTFields concomitant with modFOLFIRINOX for pancreatic adenocarcinoma metastatic.
Treatment: TTFields concomitant with modFOLFIRINOX — The purpose of this clinical trial is to assess the safety and tolerability of TTFields in combination with chemotherapy in adults with metastatic pancreatic adenocarcinoma based on treatment-emergent adverse events of chemotherapy (modFOLFIRINOX) or device (TTFields). The main questions it aims to answer are: * Is TTFields treatment safe for the patients in combination with modFOLFIRINOX? * Are participants compliant with the treatment? * Is Is TTFields treatment effective in combination with modFOLFIRINOX against metastatic pancreatic adenocarcinoma?
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
Exception: neoadjuvant or adjuvant chemotherapy allowed if at least six months have elapsed since last chemotherapy treatment
Previous treatment with chemotherapy for metastatic pancreatic ductal adenocarcinoma
Cannot have received: radiation therapy
Exception: allowed if completed more than 14 days prior to C1D1 and no persistence of radiation-related adverse effects
Previous radiation therapy within 14 days prior to C1D1 and/or persistence of radiation-related adverse effects
Cannot have received: (brivudine, sorivudine, analogues)
Patients who have received brivudine, sorivudine or analogues 4 weeks prior to Fluoracile administration
Lab requirements
Blood counts
WBC ≥ 2.5 x 10^9/L; ANC ≥ 1.5 x 10^9/L without G-CSF; Platelet count ≥ 100 x 10^9/L without transfusion; Hemoglobin ≥ 9 g/dL (transfusion allowed)
Kidney function
Serum creatinine ≤ 1.5 x ULN or Creatinine Clearance ≥ 30 ml/min (Cockcroft-Gault)
Liver function
Serum bilirubin ≤ 1.5 x ULN (≤ 3 x ULN for Gilbert's disease); AST, ALT ≤ 5 x ULN; Albumin ≥ 2.5 g/dL; INR and aPTT ≤ 1.5 x ULN
Adequate hematologic and organ function, defined by the following laboratory test results, obtained during the screening period and before C1D1.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify